Does the Dose of Standard Adjuvant Chemotherapy Affect the Triple-negative Breast Cancer Benefit from Extended Capecitabine Metronomic Therapy? An Exploratory Analysis of the SYSUCC-001 Trial.
Ying ChenWen-Xia LiJia-Hua WuGeng-Hang ChenChun-Min YangHai LuXi WangShu-Sen WangHeng HuangLi CaiLi ZhaoRou-Jun PengYing LinJun TangJian ZengLe-Hong ZhangYong-Li KeXian-Ming WangXin-Mei LiuAn-Qin ZhangFei XuXi-Wen BiJia-Jia HuangWeiwei XiaoDan-Mei PangCong XueYan-Xia ShiZhen Yu HeHuan-Xin LinXin AnWen XiaYe CaoYing GuoRuo-Xi HongKui-Kui JiangYong-Yi ZhongGe ZhangPiyawan TienchaianandaMasahiro OikawaZhong-Yu YuanQian-Jun ChenPublished in: Breast cancer (Dove Medical Press) (2024)
This study found the dose reduction of adjuvant taxane might negatively impact the efficacy of capecitabine. Therefore, the reduction of anthracycline dose over paclitaxel should be given priority during conventional adjuvant chemotherapy, if patients need dose reduction and plan for extended capecitabine.
Keyphrases
- phase iii
- metastatic breast cancer
- end stage renal disease
- locally advanced
- phase ii study
- ejection fraction
- newly diagnosed
- clinical trial
- chronic kidney disease
- early stage
- stem cells
- randomized controlled trial
- prognostic factors
- peritoneal dialysis
- squamous cell carcinoma
- open label
- radiation therapy
- phase ii
- patient reported outcomes
- mesenchymal stem cells
- rectal cancer
- bone marrow
- cell therapy
- patient reported
- double blind